

**In the Claims:**

1. (Cancelled)
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Withdrawn) DNA sequence encoding an adjuvant comprising at least the fragment of the P40 protein *Klebsiella pneumoniae*, said fragment having the amino acid sequence of SEQ ID No: 8.
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Withdrawn) A pharmaceutical composition comprising said DNA sequence of claim 7, and a pharmaceutically acceptable carrier.
17. (Withdrawn) A vaccine for intramuscular or intradermal administration comprising said DNA sequence of claim 7.

18. (Cancelled)

19. (Currently Amended) ~~A Process~~ process for increasing the immunogenicity of an antigen or a hapten, characterized in that the said process comprises the step of attaching the antigen or the hapten is attached to an adjuvant to form an immunogenic complex, said adjuvant comprising ~~the a fragment having the sequence 127 to 179~~ (SEQ ID No. 8) of the P40 protein of *Klebsiella K. pneumoniae pneumoniae* having the sequence SEQ ID No. 2.

20. (Currently Amended) ~~The Process~~ process according to claim 19, characterized in that said adjuvant is ~~the a fragment having the sequence 108 to 179~~ (SEQ ID No. 6) of the P40 protein of *K. pneumoniae* ~~having the sequence ID No. 2~~ *Klebsiella pneumoniae*.

21. (Currently Amended) ~~The Process~~ process according to claim 19, characterized in that said adjuvant is ~~the a fragment having the sequence 1 to 179~~ (SEQ ID No. 4) of the P40 protein of *K. pneumoniae* ~~having the sequence ID No. 2~~ *Klebsiella pneumoniae*.

22. (Currently Amended) ~~The Process~~ process according to claim 19, characterized in that said adjuvant is the P40 protein of *K. pneumoniae* *Klebsiella pneumoniae* having the sequence ID No. 2.

23. (Cancelled)

24. (Currently Amended) ~~The Process~~ process according to claim 19, characterized in that said antigen or ~~a the~~ hapten consists of ~~a~~ an immunogenic fragment of the G protein of the respiratory syncytial virus (RSV).

25. (Currently Amended) ~~The Process~~ process according to claim 19, characterized in that said antigen or the a hapten is attached to the adjuvant by a covalent bond.

26. (Currently Amended) The ~~Process~~ process according to claim 19, characterized in that said antigen or the hapten is attached to the adjuvant by chemical coupling.
27. (Currently Amended) The ~~Process~~ process according to claim 19, characterized in that said antigen or the hapten is fused to the adjuvant by genetic manipulation.
28. (Currently Amended) The ~~Process~~ process according to claim 19, characterized in that said antigen or the a hapten which is attached to the adjuvant, is fused to a protein which is a receptor for a serum protein.
29. (Currently Amended) The ~~Process~~ process according to claim 19, characterized in that said antigen or the a hapten which is attached to the adjuvant, is fused to a protein which is a receptor for the human serum albumin.